Drug-Induced Liver Injury in Children: Clinical Observations, Animal Models, and Regulatory Status.

摘要: Drug-induced liver injury in children (cDILI) accounts for about 1% of all reported adverse drug reactions throughout age groups, less than 10% clinical DILI cases, and around 20% acute failure cases children. The overall susceptibility has been assumed to be lower adults. Nevertheless, controversial evidence is emerging children's sensitivity DILI, with relative appearing highly drug-specific. culprit drugs cDILI are similar but not identical adults (aDILI). This demonstrated by recent findings that a frequently associated aDILI (amoxicillin/clavulanate) was rarely the basiliximab caused only aDILI. fatality studies ranged from 4% 31%. According US Food Drug Administration-approved labels, valproic acid, dactinomycin, ampicillin appear more likely cause cDILI. In contrast, deferasirox, isoniazid, dantrolene, levofloxacin Animal models have explored mimic increased acid hepatotoxicity or decreased acetaminophen halothane hepatotoxicity. However, most drugs, animal readily available, underlying mechanisms differential between remain hypothetical. Diagnosis tools yet available. A critical need exists fill knowledge gaps review article provides an overview specific